Abstract
Cutaneous lupus erythematosus (LE) may present in a variety of clinical forms. Three recognized subtypes of cutaneous LE are acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), and chronic cutaneous LE (CCLE). ACLE may be localized (most often as a malar or ‘butterfly’ rash) or generalized. Multisystem involvement as a component of systemic LE (SLE) is common, with prominent musculoskeletal symptoms. SCLE is highly photosensitive, with predominant distribution on the upper back, shoulders, neck, and anterior chest. SCLE is frequently associated with positive anti-Ro antibodies and may be induced by a variety of medications. Classic discoid LE is the most common form of CCLE, with indurated scaly plaques on the scalp, face, and ears, with characteristic scarring and pigmentary change. Less common forms of CCLE include hyperkeratotic LE, lupus tumidus, lupus profundus, and chilblain lupus. Common cutaneous disease associated with, but not specific for, LE includes vasculitis, livedo reticularis, alopecia, digital manifestations such as periungual telangiectasia and Raynaud phenomenon, photosensitivity, and bullous lesions. The clinical presentation of each of these forms, their diagnosis, and the inter-relationships between cutaneous LE and SLE are discussed. Common systemic findings in SLE are reviewed, as are diagnostic strategies, including histopathology, immunopathology, serology, and other laboratory findings.
Treatments for cutaneous LE initially include preventive (e.g. photoprotective) strategies and topical therapies (corticosteroids and topical calcineurin inhibitors). For skin disease not controlled with these interventions, oral antimalarial agents (most commonly hydroxychloroquine) are often beneficial. Additional systemic therapies may be subdivided into conventional treatments (including corticosteroids, methotrexate, thalidomide, retinoids, dapsone, and azathioprine) and newer immunomodulatory therapies (including efalizumab, anti-tumor necrosis factor agents, intravenous immunoglobulin, and rituximab). We review evidence for the use of these medications in the treatment of cutaneous LE.
Similar content being viewed by others
References
Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2004: 15–64
Kuhn A, Sontheimer RD, Ruzicka T. Clinical manifestations of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Chapter 6. Heidelberg: Springer Verlag, 2005: 59–92
Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006 Sep-Oct; 24 (5): 348–62
Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004 Feb; 33 (4): 217–30
Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006 Aug; 54 (8): 2550–7
Vitali C, Doria A, Tincani A, et al. International survey on the management of patients with SLE: I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol 1996 Nov-Dec; 14 Suppl. 16: S17–22
Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar; 72 (2): 113–24
Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol 1985 Jul-Sep; 3 (3): 58–68
Bielsa I, Herrero C, Font J, et al. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987 Jun; 16 (6): 1265–7
De Spain J, Clark DP. Subacute cutaneous lupus erythematosus presenting as erythroderma. J Am Acad Dermatol 1988 Aug; 19 (2 Pt 2): 388–92
Scheinman PL. Acral subacute cutaneous lupus erythematosus: an unusual variant. J Am Acad Dermatol 1994 May; 30 (5 Pt 1): 800–1
Sontheimer RD, Maddison PJ, Reichlin M, et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982 Nov; 97 (5): 664–71
Mond CB, Peterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 1989 Feb; 32 (2): 202–4
Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity 2005 Nov; 38 (7): 507–18
Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15 (11): 757–61
Vedove CD, Del Giglio M, Schena D, et al. Drug-induced lupus erythematosus. Arch Dermatol Res 2009 Jan; 301 (1): 99–105
Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patientoriented translational clinical investigation. Arch Dermatol Res 2009 Jan; 301 (1): 65–70
De Berker D, Dissaneyeka M, Burge S. The sequelae of chronic cutaneous lupus erythematosus. Lupus 1992 May; 1 (3): 181–6
Wilson CL, Burge SM, Dean D, et al. Scarring alopecia in discoid lupus erythematosus. Br J Dermatol 1992 Apr; 126 (4): 307–14
Tebbe B, Mansmann U, Wollina U, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement: a multicenter study on 96 patients. Acta Derm Venereol 1997 Jul; 77 (4): 305–8
Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev 2005 Apr; 4 (4): 219–23
Daldon PE, Macedo de Souza E, Cintra ML. Hypertrophic lupus erythematosus: a clinicopathological study of 14 cases. J Cutan Pathol 2003 Aug; 30 (7): 443–8
Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Verrucous lesion in patients with discoid lupus erythematosus: clinical, histopathological and immunofluorescence studies. Br J Dermatol 1978 May; 98 (5): 507–20
Ahmed AR, Schreiber P, Abramovits W, et al. Coexistence of lichen planus and systemic lupus erythematosus. J Am Acad Dermatol 1982 Oct; 7 (4): 478–83
Massone C, Kodama K, Salmhofer W, et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J Cutan Pathol 2005 Jul; 32 (6): 396–404
Carducci M, Mussi A, Lisi S, et al. Lupus mastitis: a 2-year history of a single localization of lupus erythematosus mimicking breast carcinoma. J Eur Acad Dermatol Venereol 2005 Mar; 19 (2): 260–2
Ruiz H, Sánchez JL. Tumid lupus erythematosus. Am J Dermatopathol 1999 Aug; 21 (4): 356–60
Rémy-Leroux V, Léonard F, Lambert D, et al. Comparison of histopathologic-clinical characteristics of Jessner’s lymphocytic infiltration of the skin and lupus erythematosus tumidus: multicenter study of 46 cases. J Am Acad Dermatol 2008 Feb; 58 (2): 217–23
Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus: review of 60 patients. Photochem Photobiol 2001 May; 73 (5): 532–6
Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996 Sep; 135 (3): 355–62
Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus: a review of literature. Clin Rheumatol 2008 Aug; 27 (8): 949–54
Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007 Apr; 80 (4): 811–5
Lépez-Labady J, Villarroel-Dorrego M, González N, et al. Oral manifestations of systemic and cutaneous lupus erythematosus in a Venezuelan population. J Oral Pathol Med 2007 Oct; 36 (9): 524–7
Lourenço SV, de Carvalho FR, Boggio P, et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of the inflammatory infiltrate. J Cutan Pathol 2007 Jul; 34 (7): 558–64
Nico MM, Vilela MA, Rivitti EA, et al. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol 2008 Jul-Aug; 18 (4): 376–81
Lee LA. Neonatal lupus: clinical features and management. Pediatr Drugs 2004; 6 (2): 71–8
Weston WL, Morelli JG, Lee LA. The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus. J Am Acad Dermatol 1999 May; 40 (5 Pt 1): 675–81
Boh EE. Neonatal lupus erythematosus. Clin Dermatol 2004; 22 (2): 125–8
Martin V, Lee LA, Askanase AD, et al. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46 (9): 2377–83
Dhar JP, Essenmacher LM, Ager JW, et al. Pregnancy outcomes before and after a diagnosis of systemic lupus erythematosus. Am J Obstet Gynecol 2005 Oct; 193 (4): 1444–55
Molad Y. Systemic lupus erythematosus and pregnancy. Curr Opin Obstet Gynecol 2006 Dec; 18 (6): 613–7
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 Nov; 25 (11): 1271–7
Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clin Dermatol 2004 Mar-Apr; 22 (2): 121–4
Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006 Mar; 85 (2): 95–104
Satirapoj B, Wongchinsri J, Youngprang N, et al. Predictors of renal involvement in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2007 Mar; 25 (1): 17–25
Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992 Apr; 21 (5): 275–86
Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005 Jul; 84 (4): 225–30
Kriseman YL, Nash JW, Hsu S. Criteria for the diagnosis of antiphospholipid syndrome in patients presenting with dermatologic symptoms. J Am Acad Dermatol 2007 Jul; 57 (1): 112–5
Sahin M, Duzgun N, Tunc SE, et al. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? Clin Rheumatol 2007 Feb; 26 (2): 154–60
Tebbe B, Hoffmann S, Orfanos CE. Course and prognosis of subacute cutaneous lupus erythematosus: a prospective study of 34 patients [in German]. Hautarzt 1994 Oct; 45 (10): 690–5
Weinstein C, Miller MH, Axtens R, et al. Lupus and non-lupus cutaneous manifestations in systemic lupus erythematosus. Aust N Z J Med 1987 Oct; 17 (5): 501–6
Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995 Jun; 132 (6): 921–8
Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993 Jan; 100 (1): 8S–34S
Burrows NP, Bhogal BS, Black MM, et al. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br J Dermatol 1993 Mar; 128 (3): 332–8
Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000 Nov; 39 (11): 1249–54
Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. Lupus 2004; 13 (11): 851–3
Gräfe A, Wollina U, Tebbe B, et al. Fibromyalgia in lupus erythematosus. Acta Derm Venereol 1999 Jan; 79 (1): 62–4
Björnådal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 2004 Apr; 31 (4): 713–9
Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007 Aug; 28 (4): 441–50
Boumpas DT, Austin 3rd HA, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts: part 1. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995 Jun 15; 122 (12): 940–50
Parikh-Patel A, White RH, Allen M, et al. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008 Oct; 19 (8): 887–94
Burnham TK, Fine G. The immunofluorescent “band” test for lupus erythematosus: 3. Employing clinically normal skin. Arch Dermatol 1971 Jan; 103 (1): 24–32
Font J, Cervera R, Navarro M, et al. Systemic lupus erythematosus in men: clinical and immunological characteristics. Ann Rheum Dis 1992 Sep; 51 (9): 1050–2
Smith CD, Marino C, Rothfield NF. The clinical utility of the lupus band test. Arthritis Rheum 1984 Apr; 27 (4): 382–7
Cardinali C, Caproni M, Fabbri P. The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. Clin Exp Rheumatol 1999 Jul-Aug; 17 (4): 427–32
Olhoffer IH, Peng SL, Craft J. Revisiting autoantibody profiles in systemic lupus erythematosus. J Rheumatol 1997 Feb; 24 (2): 297–302
Ostrowski RA, Robinson JA. Antiphospholipid antibody syndrome and autoimmune diseases. HematolOncol Clin North Am 2008 Feb; 22 (1): 53–65
Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000 Jun; 42 (6): 983–7
Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004 Sep; 50 (9): 3045–6
Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001; (1): CD002954
Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002 Jan-Feb; 12 (1): 50–2
Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating themalar rash of systemic lupus erythematosus. Br J Dermatol 2003 Feb; 148 (2): 353–6
Chambers CA. Topical tacrolimus for cutaneous lupus erythematosus. Br J Dermatol 2003 Apr; 148 (4): 829
Böhm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus: a report of three cases. Dermatology 2003; 207 (4): 381–5
Drüke A, Gambichler T, Altmeyer P, et al. 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatolog Treat 2004 Jan; 15 (1): 63–4
Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004 Nov; 43 (11): 1383–5
Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004 Sep; 51 (3): 407–10
Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008 Apr; 64 (4): 337–41
Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, doubleblind, bilateral comparison study. Br J Dermatol 2007 Jan; 156 (1): 191–2
Sugano M, Shintani Y, Kobayashi K, et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006 Dec; 33 (12): 887–91
Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009 Jan; 301 (1): 93–8
Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991 May; 47 (5): 351–5
Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999 Dec; 41 (6): 1049–50
Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992 Nov; 127 (5): 513–8
Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9 (2): 92–5
Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002 Jul; 109 (7): 1377–82
Heath M, Raugi GJ. Evidence-based evaluation of immunomodulatory therapy for the cutaneousmanifestations of lupus. Adv Dermatol 2004; 20: 257–91
Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005 Mar; 118 (3): 246–50
Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005; 14 (6): 434–9
Wenzel J, Brähler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005 Jul; 153 (1): 157–62
Kuhn A, Specker C, Ruzicka T, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002 Apr; 46 (4): 600–3
Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001; 10 (3): 162–4
Callen JP, Spencer LV, Burruss JB, et al. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991 Apr; 127 (4): 515–22
Neri R, Mosca M, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999; 8 (3): 240–3
Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol 2000 Nov; 41 (4): 234–7
Holtman JH, Neustadt DH, Klein J, et al. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990 Sep; 17 (9): 1222–5
Camisa C. Vesiculobullous systemic lupus erythematosus: a report of four cases. J Am Acad Dermatol 1988 Jan; 18 (1 Pt 1): 93–100
Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986; 172 (4): 214–7
McCormack LS, Elgart ML, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984 Sep; 11 (3): 397–401
Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986 Jan; 11 (1): 102–3
Hall RP, Lawley TJ, Smith HR, et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982 Aug; 97 (2): 165–70
Ujiie H, Shimizu T, Ito M, et al. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol 2006 Mar; 142 (3): 399–401
Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982 Jan; 106 (1): 105–6
Bezerra EL, Vilar MJ, da Trindade Neto PB, et al. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005 Oct; 52 (10): 3073–8
Wozniacka A, Salamon M, Lesiak A, et al. The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis. Clin Rheumatol 2007 Jul; 26 (7): 1176–9
Saeki Y, Ohshima S, Kurimoto I, et al. Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 2000; 9 (5): 390–2
Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003 Jan; 48 (1): 166–73
Wenzel J, Bieber T, Uerlich M, et al. Systemic treatment of cutaneous lupus erythematosus [in German]. J Dtsch Dermatol Ges 2003 Sep; 1 (9): 694–704
Newton RC, Jorizzo JL, Solomon Jr AR, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986 Feb; 122 (2): 170–6
Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 1990 Oct; 29 (8): 587–90
Vena GA, Coviello C, Angelini G. Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus [in Italian]. G Ital Dermatol Venereol 1989 Jun; 124 (6): 311–5
Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991 Jan; 24 (1): 49–52
Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol 1987 Aug; 17 (2 Pt 2): 364–8
Rubenstein DJ, Huntley AC. Keratotic lupus erythematosus: treatment with isotretinoin. J Am Acad Dermatol 1986 May; 14 (5 Pt 2): 910–4
Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfullywith acitretin asmonotherapy. J Dermatol 2005 Jun; 32 (6): 482–6
Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988 Jun; 124 (6): 897–902
Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995 Feb; 21 (1): 99–115
Schanz S, Ulmer A, Rassner G, et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002 Jul; 147 (1): 174–8
Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005 May-Jun; 23 (3): 393–6
Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 2007 Sep-Oct; 36 (5): 329–37
Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007 Jul; 143 (7): 873–7
Hamprecht A, Tüting T, Bieber T, et al. Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clin Exp Dermatol 2008 May; 33 (3): 347–8
Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol 2006 May; 54 (5): 892–5
Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006 May; 54 (5 Suppl.): S242-36
Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): S139–42
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to antitumor necrosis factor alpha agents. Semin Arthritis Rheum 2008 Jun; 37 (6): 381–7
Sheth N, Greenblatt D, Patel S, et al. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol 2007 Sep; 32 (5): 593–4
Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 Jul; 86 (4): 242–51
Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004 Jan; 15 (1): 46–50
Lampropoulos CE, Hughes GR, D’Cruz DP. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 2007 Jun; 26 (6): 981–3
Kreuter A, Hyun J, Altmeyer P, et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005; 85 (6): 545–7
Uthman I, Taher A, Abbas O, et al. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008; 216 (3): 257–9
Gordon C, Wallace DJ, Shinada S, et al. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology (Oxford) 2008 Mar; 47 (3): 334–8
Wenzel J, Zahn S, Bieber T, et al. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res 2009 Jan; 301 (1): 83–6
Meller S, Winterberg F, Gilliet M, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005 May; 52 (5): 1504–16
Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol 2008 Jun; 14 (3): 166–8
Crispín JC, Díaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus 2005; 14 (6): 495–6
Flores A, Olivé A, Feliu E, et al. Systemic lupus erythematosus following interferon therapy [letter]. Br J Rheumatol 1994 Aug; 33 (8): 787
Acknowledgments
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Walling, H.W., Sontheimer, R.D. Cutaneous Lupus Erythematosus. AM J Clin Dermatol 10, 365–381 (2009). https://doi.org/10.2165/11310780-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11310780-000000000-00000